Helping The Neediest Patients: Stopping Insurers’ Rejection Of Prescription Medications | By: Michael D. Shaw

Oct 27, 2016

Are cancer drugs worth the cost?

Read More ›

Oncologists knock ICER's lung cancer cost-effectiveness review | By: Eric Sagonowsky

Oct 20, 2016

Ahead of an ICER meeting to review evidence and vote on cost-effectiveness ratings for non-small cell lung cancer treatments, a group of oncologists is airing “serious concerns” about the organization’s assessment techniques. The docs have laid out principles that they believe should serve as the “start of a discussion” around building a value framework.

Read More ›

Cancer patients bring urgent voices of value to St. Louis | By: Jonathan Wilcox

Oct 18, 2016

Read More ›

Aimed Alliance Calls on ICER to Prevent Discrimination of Patients with Non-Small Cell Lung Cancer

Sep 30, 2016

Washington, DC – September 29, 2016 – The Alliance for the Adoption of Innovations in Medicine (Aimed Alliance)—urged the Institute for Clinical and Economic Review (ICER) to consider patient-defined value of non-small cell lung cancer (NCSLC) treatments and the discrimination that can result from drug rationing proposals.  
 

Read More ›

The Bonnie J. Addario Lung Cancer Foundation (ALCF) Comments to ICER on Their Scoping Document for Certain Non-Small Cell Lung Cancer Treatments

Sep 19, 2016

The following statement was issued by the Bonnie J. Addario Lung Cancer Foundation (ALCF) in response to the scoping document evaluating certain lung cancer drugs released by the Institute for Clinical Economic Review (ICER):

Read More ›

The Lung Cancer Action Network (LungCAN) Submits Comments to ICER on Advanced Non-Small Cell Lung Cancer Draft Evidence Report

Sep 16, 2016

The Lung Cancer Action Network (LungCAN), an association of 501(c)(3) nonprofit organizations advocating for and serving the lung cancer community, submitted comments to ICER on the institute's Draft Evidence Report for Advanced Non-Small Cell Lung Cancer treatments. It was signed by a coalition of twelve lung cancer organizations and patient advocates.

Read More ›

LUNGevity Comments to ICER on Draft Scoping Document for Non-Small Cell Lung Cancer | By: Andrea Ferris

Jul 1, 2016

On behalf of LUNGevity Foundation, the nation’s preeminent lung cancer nonprofit, that funds research, provides education and support, and builds communities for the 224,390 Americans diagnosed with lung cancer each year and the over 400,000 Americans living with the disease, we appreciate the opportunity to respond to the request for comments regarding ICER’s draft scoping document for non-small cell lung cancer.

Read More ›

Lung Cancer Alliance Comments to ICER on Draft Scoping Document for Non-Small Cell Lung Cancer

Jun 29, 2016

Lung Cancer Alliance (LCA) appreciates the opportunity to provide comments to the Institute for Clinical and Economic Review’s (ICER) scope of work on its Treatment Options for Advanced Non-Small-Cell Lung Cancer: Effectiveness, Value, and Value-Based Price Benchmarks. LCA is a nationally recognized trusted source of information, advocacy and support for the lung cancer community.

Read More ›

Bristol-Myers Squibb Public Comments to ICER on Draft Scoping for Non-Small Cell Lung Cancer

Jun 29, 2016

At Bristol-Myers Squibb, we are committed to putting patients and their families first in their fight against serious diseases. Through our pioneering Immuno-Oncology research, we are transforming the way cancer is treated and expanding our approach to provide meaningful, longterm outcomes across the many stages of the disease. It is essential that the healthcare community continue to foster an environment of innovation in order to fulfill the promise of Immuno-Oncology therapies: longer survival and enhanced quality of life for patients.

Read More ›

Patients Rising Public Comments to ICER on Draft Scoping for Non-Small Cell Lung Cancer | By: Terry Wilcox

Jun 28, 2016

Patients Rising is a Washington, DC-based non-profit organization with a very specific mission: we advocate for access to vital therapies and services for all patients with life-threatening and chronic diseases.  That is why Patients Rising is committed to bringing forward the patient voice as part of a balanced dialogue with providers, payers, policymakers and the advocacy community to address the complement of cost and access challenges Americans with serious diseases face every day.

Read More ›

Pages